



PATENT  
FI5028-US-CNT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : AUTHELIN ET AL. EXAMINER : JOYNES, ROBERT  
SERIAL NO. : 09/871,876 ART UNIT : 1615  
FILED : JUNE 1, 2001  
FOR : MILLING PROCESS FOR THE PRODUCTION OF FINELY MILLED  
MEDICINAL SUBSTANCES

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that this correspondence is being by  
EXPRESS MAIL with EXPRESS MAIL LABEL  
EL964839962US to Mail Stop RCE, Commissioner for  
Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at  
on January 21, 2004

*Barrie Klein 1/21/04*  
(Signature and Date)

AMENDMENT AFTER FINAL UNDER 37 C.F.R. 1.116  
EXPEDITED PROCEDURE  
GROUP ART UNIT 1632

MAIL STOP RCE  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Dear Sir:

In response to the Office Action dated July 24, 2003 and thus due for response on  
October 24, 2003, please consider the following remarks and amendments for purposes of  
allowance, or alternatively, to narrow the issues on appeal. Applicants concurrently file herewith  
the following documents:

RECEIVED  
JAN 27 2004  
TECH CENTER 1600/2900

*Change of Attorney/Agent*

Applicants request that future communications regarding this Application be directed to the following:

Ross J. Oehler, Esq.  
Aventis Pharmaceuticals Inc.  
Patent Department  
Route 202/206  
P.O. Box 6800, Bridgewater, NJ 08807-0800  
908-231-4000 (Tel.)  
908-231-2626 (Fax)


*Fees*

No fees are believed to be necessitated by the instant response. However, should this be in error, authorization is hereby given to charge Deposit Account no. 18-1982 for any underpayment, or to credit any overpayments.

CONCLUSION

Applicants respectfully request entry of the foregoing amendments and remarks in the file history of the instant Application. The Claims as amended are believed to be in condition for allowance, and reconsideration and withdrawal of all of the outstanding rejections is therefore believed in order. Early and favorable action on the claims is earnestly solicited.

Respectfully submitted,



William C. Coppola  
Registration No. 41,686

AVENTIS PHRAMACEUTICALS INC.  
Route 202-206; Mail Code: D-303A  
P.O. Box 6800  
Bridgewater, NJ 08807